Document:

Separation Agreement, dated July 15, 2008-- Judson Cooper

 Exhibit 10.5 
 LEV PHARMACEUTICALS, INC. 
 675 Third Avenue 
 Suite 2200 
 New York, NY 10017 
 July 15, 2008 
 Judson Cooper 
 c/o Lev Pharmaceuticals, Inc. 
 675 Third Avenue 
 Suite 2200 
 New York, NY 10017 
 Dear Mr. Cooper: 
 Reference is made to the Agreement and Plan of Merger by and among ViroPharma Incorporated
(“Buyer”), HAE Acquisition Corp (“Sub”), and Lev Pharmaceuticals, Inc. (the “Company”), dated July 15, 2008 (the “Merger Agreement”) and the Second Amended and Restated Employment Agreement between
you and the Company dated December 20, 2007 (the “Employment Agreement”). Unless otherwise specified herein, capitalized terms used herein without definition have the meanings ascribed in the Merger Agreement or the Employment
Agreement, as applicable. 
 This letter agreement (the “Agreement”) sets forth our mutual agreement concerning
(i) your resignation as an executive officer and employee of the Company effective immediately after the closing of the transactions (the “Merger”) contemplated by the Merger Agreement (the “Closing”),
(ii) the payments that will be made to you and (iii) amends the restrictions on competition set forth in the Employment Agreement. 
 1. Resignation. Your employment with the Company and its subsidiaries and affiliates will terminate in all capacities immediately after the Closing (the “Effective Time”). 
 2. Payments. The Company will provide you with the following payments and benefits: 
 (a) An amount equal to $14,365,000, which represents 3.25% of the Enterprise Value ($442,000,001) of the Company without regard to the Contingent Value
Rights issued in connection with the Merger (such amount being, the “Total Transaction Amount”). The Total Transaction Amount shall be paid as follows: 
 (i) That portion of the Total Transaction Amount which is attributable to the Transaction Fee, or $6,630,000, shall be paid in a lump sum,
subject to receipt by the Company and Buyer of a mutual release in the form attached hereto signed by You, on the Closing Date. 
 (ii) That portion of the Total Transaction Amount which is attributable to the severance amounts payable to you pursuant to Section 8(b) of the Employment Agreement (the “Severance Amount”) shall be paid in a lump sum
on the day after the six-month period starting on the date of Closing. To illustrate, if the Closing occurs on September 30, 2008, the Severance Amount would be $6,377,823 and the payment will be made on March 31, 2009. 

 (iii) The remaining portion of the Total Transaction Amount (less the parties good faith
determination of the cost of the benefits provided in Section 2(c) below) which is attributable to the Gross-Up Payment described in Section 8(e) of the Employment Agreement (the “Gross-Up Amount”) shall be paid to you
when such taxes are remitted but in no event later than the last day of the taxable year following the taxable year in which you are required to pay the Excise Tax. 
 In accordance with Section 8(c) of the Employment Agreement, subject to receipt by the Company and Buyer of a mutual release in the form attached hereto signed by you, on the Closing Date the Company will place
the Severance Amount and the Gross-Up Amount into a “rabbi trust.” Such trust shall be maintained pursuant to a standard rabbi trust arrangement by and among you, the Company, and an independent trustee providing for the timely payment of
the amounts held in the trust (the “Trust Arrangement”). The Trust Arrangement shall be maintained until all sums held in the trust have been paid. 
 (b) As soon as practicable following, but in no event more than thirty (30) days following, the date that the First CVR Payment Amount is deemed earned, the Enterprise Value shall be increased to $522,363,637 and
the Buyer shall pay you an additional amount equal to $1,205,455 as an additional Transaction Fee payment on such date. As soon as practicable following, but in no event more than thirty (30) days following, the date that the Second CVR Payment
Amount is deemed earned, the Enterprise Value will increase to $602,727,274 and the Buyer shall pay you an additional amount equal to $1,205,455 as an additional Transaction Fee payment on such date. Any additional Gross-Up Payments applicable to
each additional Transaction Fee payments and to the payment of the CVRs up to the applicable Cap (which in each case increases by $2,611,818) shall be paid by the Company within the time specified in Section 2(a)(iii) above. The first CVR
Payment Amount and the Second CVR Payment Amount shall not be subject to the rabbi trust provisions described above and shall be paid in accordance with this Section 2(b). 
 (c) Continuation of Insurance Coverage. As provided in Section 7(e)(ii)(B) of the Employment Agreement, the Company or the Buyer will
continue (or provide comparable substitute coverage) your health, dental, disability and life insurance coverage as in effect on the date of your termination, and pay the applicable premiums, until the earlier of (a) December 31, 2012 or
(b) the date on which you are covered under another comparable plan. You agree to notify the Company in writing within 15 (fifteen) days in the event that you obtain coverage under another such plan. 
 (d) 401(k) Plan. You will be entitled to receive your vested accrued benefits under the Company’s 401(k) plan in accordance with the terms
and conditions of such plan. 
 (e) Options; Restricted Stock. Your options to purchase the Company’s Common stock and your
restricted shares of Common Stock will be deemed fully vested at the Closing and will be treated as contemplated in the Merger Agreement. 
 (f) Accrued Compensation. You shall also be entitled to receive the Accrued Compensation in accordance with the Employment Agreement. 
  

 - 2 - 

 3. Restrictive Covenants. 
 (a) Non-competition. Effective as of the Closing, Section 9(d) of the Employment Agreement is amended in its entirety to read as follows:

 “Cooper agrees that during the period beginning on the Closing Date and ending three years after the Closing Date (the
“Noncompete Restricted Period”), he shall not, except for a Permitted Activity, directly or indirectly, for his own benefit or for the benefit of any other person or entity (whether as an officer, director, employee, partner,
joint venturer, consultant, investor or otherwise): 
  

	 	(i)	Engage in direct competition with the Business (as defined below); 

  

	 	(ii)	Solicit, encourage or induce any person or entity, or any affiliate of any person or entity, which, as of the Closing Date is a vendor or customer of the Company, to sever its, or
not enter into a, or reduce a, relationship with the Company, Sub or Buyer relating to the Business; or 

  

	 	(iii)	For purposes hereof, the term “Business” shall mean the development and commercialization of therapeutic products for the (x) sole and primary purpose
of the treatment and/or prevention of hereditary angioedema and/or (y) involving a human C-1 esterase inhibitor. 

 For purposes hereof,
“Permitted Activity” means (i) the ownership of publicly-traded securities of any entity not exceeding 3% of the total amount outstanding of such securities, (ii) following Cooper’s notice to Buyer, the direct
employment with a government entity or university (or contracting relationship with such an entity or university solely as an individual contributor) other than work performed for a university that directly benefits a competitor of the Company or is
performed in connection with a project the subject matter of which is in direct competition with the products or services offered by the Company as of the Closing Date or (iii) accepting employment (or performing services for) any entity whose
business is diversified but which engages in the Business, so long as (A) Cooper does not render any services or assistance to any division or part of such entity that is in any way engaged in the Business, and (B) Buyer shall have
received, prior to Cooper rendering any services or assistance, written assurance from such entity that Cooper shall not render any services or assistance to any division or part of such entity that is in any way engaged in the Business; provided
that the Permitted Activity does not include (a) any operational management position in any such entity referenced in (i) above or (b) any activity described in Section 9(d)(ii) above. 
 (b) Non-solicitation of Employees. Effective as of the Closing, Section 9(e) of the Employment Agreement is amended in its entirety to read
as follows: 
 “Cooper agrees that during the period beginning on the Closing Date and ending one year after the Closing
Date, he shall not (i) solicit for employment or recruit (whether as an employee, principal, consultant or otherwise) any person who is an employee of or consultant to the Company immediately prior to the Closing Date, or (ii) induce or
encourage any such person to sever his/her relationship with the Company or Buyer; provided, that the provisions of this Section 9(e) shall not be violated if such employee or consultant or former employee or consultant (x) responds to a
general advertisement for services not specifically directed at such person, or (y) has been terminated by the Company or the Buyer. This provision shall not apply to Joshua Schein.” 
  

 - 3 - 

 (c) Notwithstanding anything to the contrary, you shall not be required to comply with any provision of
Sections 9(d) or 9(e) of the Employment Agreement if the amounts required to be paid pursuant to Section 2 of this Agreement are not timely paid. 
 4. Communications. You and the Buyer agree that the press release and any related statements regarding your resignation will be in the form to be mutually agreed upon, and that no subsequent comments should be
made to the media or through other public statements by either party or by any subsidiary, officer or director of the Buyer regarding your departure that are inconsistent with such statement. From and after the Effective Time, you will refrain from
taking actions or making public statements, written or oral, which denigrate, disparage or defame the goodwill or reputation of the Buyer and its subsidiaries and their former and current executive officers and directors. From and after the
Effective Time, the Buyer will refrain, and will cause its executive officers and directors to refrain, from taking actions or making public statements, written or oral, which denigrate, disparage or defame your reputation. The restrictions set
forth in this Section 4 will be subject to such exceptions as are required by law or in connection with a judicial proceeding. 
 5.
Release. On or prior to the Closing Date, You, the Company, and the Buyer will enter into a mutual release in the form attached hereto. 
 6. Indemnification. The Buyer shall continue to provide, and shall cause its subsidiaries to continue to provide you with indemnification, expense advancement, exculpation of liabilities and directors and officers liability
insurance, with respect to actions or inactions by you as an officer or director of the Company (or any of its subsidiaries) prior to the Effective Time to the fullest extent permitted by law. 
 7. No Set-Off or Mitigation. The Company’s and/or the Buyer’s obligations to make the payments provided for in this Agreement and
otherwise to perform its obligations hereunder shall not be affected by any set-off, counterclaim, recoupment, defense or other claim, right or action which the Company may have against you or others. In no event shall you be obligated to seek other
employment or take any other action by way of mitigation of the amounts payable to you under any of the provisions of this Agreement, and such amounts shall not be reduced whether or not you obtain other employment (other than the obligation to
continue benefits coverage as provided in Section 2(b) above). 
 8. Miscellaneous. 
 (a) Effect on Employment Agreement. Except as set forth herein, the Employment Agreement remains in full force and effect. In the event that the
Merger has not been consummated prior to the Expiration Date (as defined in the Merger Agreement), this Agreement shall be null, void and of no further force and effect. 
 (b) Taxes. Any payments made or benefits provided to you under this Agreement will be reduced by any applicable federal and state withholding and employment taxes. Nothing herein shall amend the provisions of
the Employment Agreement that relate to the determination as to whether an Excise Tax is due and the amount of such Excise Tax. 
 (c)
Survival of Provisions. The following sections of the Employment Agreement shall survive the termination of your employment, Sections 8 (as clarified and modified herein), 9 (as modified herein), 10, 11, 12, 14, 17, 19, 21, and 22.

 (d) Legal Expenses. The Company will pay the legal fees incurred by you in connection with the Merger. 
  

 - 4 - 

 (e) Enforceability/Severability. The parties hereto affirmatively acknowledge that this
Agreement, and each of its provisions, is enforceable, and expressly agree not to challenge nor raise any defense against the enforceability of this Agreement or any of its provisions in the future. The invalidity or unenforceability of any
provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement. In the event that any provision or portion of this Agreement shall be determined to be invalid or unenforceable for any reason, the
remaining provisions or portions of this Agreement shall be unaffected thereby and shall remain in full force and effect to the fullest extent permitted by law. 
 (f) Successors. This Agreement shall be binding on you and the Company and your’s and the Company’s respective heirs, successors and assigns, including without limitation, the Buyer. Your obligations
under this Agreement may not be assigned. The obligations of the Company under this Agreement may not be assigned except to a successor to all or substantially all of the business or assets of the Company or by operation of law. In the event of your
death, all future payments hereunder will be made to your estate or designated beneficiary. 
 (g) Injunctive Relief. Notwithstanding
anything to the contrary in the Employment Agreement, any breach of the restrictive covenant obligations, including any breach of the non-competition or non-solicitation provisions shall be subject to the remedy provisions, including injunctive
relief enforced by a court of competent jurisdiction, of Section 9(f) of the Employment Agreement. 
  

			
	LEV PHARMACEUTICALS, INC.
		
	By	 	 /s/ Joshua D. Schein

	Name:	 	Joshua D. Schein
	Title:	 	Chief Executive Officer
	Dated:	 	July 15, 2008

  

			
	Accepted and Agreed:
	
	 /s/ Judson Cooper

	Judson Cooper
	Dated:	 	07/15/08
	
	ACKNOWLEDGED AND AGREED IN ALL RESPECTS
	
	ViroPharma Incorporated
		
	By	 	 /s/ Vincent J. Milano

	Name:	 	
	Title:	 	
	Dated:	 	  

  

 - 5 - 

 Annex A 
 FORM OF RELEASE 
 GENERAL RELEASE AGREEMENT 
 This is a General Release Agreement (“General Release”) between Judson Cooper (“You”), Lev Pharmaceuticals, Inc.,
(“the Company”) and ViroPharma Incorporated (“Buyer”). 
 (a) General Release. In consideration of the Company’s obligations
under the Agreement dated July 15, 2008 between Lev Pharmaceuticals, Inc., (“the Company”) and ViroPharma Incorporated (“Buyer”) (the “Agreement”) and for other valuable consideration, You hereby release and
forever discharge the Company, its subsidiaries and affiliates and each of their respective officers, employees, directors and agents (the “Company Releases”) from any and all claims, actions and causes of action (collectively,
“Claims”), including, without limitation, any Claims arising under any applicable federal, state, local or foreign law, that You may have, or in the future may possess, arising out of (x) your employment relationship with and
service as a director, employee or officer of the Company or any of its subsidiaries or affiliates, and the termination of such relationship or service, or (y) any event, condition, circumstance or obligation that occurred, existed or arose on
or prior to the date hereof; provided, however, that the release set forth herein will not apply to (A) the obligations of the Company under the Agreement and the Employment Agreement and Merger Agreement referenced therein. You
further agree that the payments and benefits described in the Agreement will be in full satisfaction of any and all claims for payments or benefits, whether express or implied, that You may have against the Company or any of its subsidiaries or
affiliates arising out of your employment relationship, your service as a director, employee or officer of the Company or any of its subsidiaries or affiliates and the termination thereof. You hereby acknowledge and confirm that You are providing
the release and discharge set forth herein only in exchange for consideration in addition to anything of value to which You are already entitled. You acknowledge and agree that if You should hereafter make any claim or demand or commence or threaten
to commence any action, claim or proceeding against the Company Releases with respect to any cause, matter or thing which is the subject of this Section (a), this General Release may be raised as a complete bar to any such action, claim or
proceeding, and the applicable Company Releasee may recover from You all costs incurred in connection with such action, claim or proceeding, including attorneys’ fees. This is a General Release except as set forth herein. By signing this
General Release, You are agreeing to forego all claims or potential claims against the Company except as set forth herein. You agree that this release will extinguish all claims which have arisen at any time up to the time You sign this General
Release except as set forth herein. 
 (b) Release of Unknown Claims. You understand and agree that the claims released herein by You are intended
to and do include any and all claims of every nature and kind whatsoever, known or unknown, suspected or unsuspected, which You have or may have against any person or entity You released above and You expressly consent that this General Release
shall be given 

  

 - 6 - 

 
full force and effect according to each and all of its expressed terms and provisions, including as well those relating to unknown and unspecified claims,
charges, demands, suits, actions, causes of action and debts, if any, and those relating to any other claims, charges, demands, suits, actions, causes of action and debts hereinabove specified. You acknowledge that You are aware that You may
hereafter discover claims or facts in addition to, or different from, those which You now know or believe to exist with respect to the subject matter covered by this General Release and which, if known or suspected at the time of executing this
General Release, may have materially affected this General Release or your decision to enter into it. Nevertheless, You hereby waive any rights, claims or causes of action that might arise as a result of such different or additional claims or facts.
You agree not to file, join in or prosecute further any lawsuits against the Company, concerning any matter in any way arising out of or relating in any way to any matter, act, occurrence, omission, practice, conduct, policy, event, or transaction
on or before the date of this General Release. By signing this General Release, You agree not to sue the Company with respect to any claims that have been released herein. You expressly represent that as of the date that You sign this General
Release, You have no pending grievances, claims, complaints, administrative charges or lawsuits against the Company or any other released party. 
 (c)
Releases: Without limiting the generality of the General Release, You specifically acknowledge and agree that, except as set forth herein, You are knowingly and voluntarily releasing each and all of the following persons, companies, and
entities from any and all claims You have or may have: Lev Pharmaceuticals, Inc. and ViroPharma Incorporated and any and all past, present, and/or future parent, subsidiary, affiliate, related business entity, employee benefit plan or fund, and its
and their respective past, present, and/or future officers, directors, employees, agents, predecessors, successors, purchasers, attorneys, assigns, and representatives. 
 (d) Company Release. The Company and its subsidiaries and affiliates, including, without limitation, the Buyer (the “Company Releasors”) hereby release and forever discharge You, your estate
and your legal representatives (the “Individual Releases”) from any and all known and unknown Claims, including, without limitation, any Claims arising under any applicable federal, state, local or foreign law, that it may have, or
in the future may possess, arising out of (x) your employment relationship with and service as a director, employee or officer of the Company or any of its subsidiaries or affiliates or predecessors, and the termination of such relationship or
service, or (y) any event, condition, circumstance or obligation that occurred, existed or arose on or prior to the date hereof; provided, however, that the release set forth herein will not apply to your obligations under this
Agreement. The Company acknowledges and agrees that if it or any other Company Releasor should hereafter make any claim or demand or commence or threaten to commence any action, claim or proceeding against You or the Individual Releases with respect
to any cause, matter or thing which is the subject of this Section, this Agreement may be raised as a complete bar to any such action, claim or proceeding, and You or the applicable Individual Release may recover from the Company Releasors all costs
incurred in connection with such action, claim or proceeding, including attorneys’ fees. 
 (e) No Waiver: The Parties recognize, acknowledge and
agree that the failure by a Party to enforce any term of this General Release shall not constitute a waiver of any rights or deprive the Party of the right to insist thereafter upon strict adherence to that or any other term of this General Release,
nor shall a waiver of any breach of this General Release constitute a waiver of any preceding or succeeding breach. No waiver of a right under any provision of this General Release shall be binding unless made in writing and signed by the Party.

  

 - 7 - 

 (f) Miscellaneous: The validity and construction of this General Release or of any of its terms or provisions
shall be determined under the laws of the State of New York, regardless of any principles of conflicts of laws or choice of laws of any jurisdiction. You represent and warrant that no person had or has or claims any interest in the claims referred
to anywhere in this General Release. You also represent and warrant that You have not heretofore assigned or transferred, or purported to assign or transfer, to any person or entity, any claim against the Company or portion thereof or interest
therein, and will not assign or otherwise transfer, any claim or demand relating to any matter covered by this General Release or the consideration to be paid pursuant thereto. The Parties agree that this General Release shall inure to the benefit
of the officers, directors, employees, agents, parents, affiliates, predecessors, successors, purchasers, assigns, and representatives of the Company. The Parties agree that this General Release shall not be modified, waived or amended except in
writing signed by each of the Parties. 
 (g) Consultation with Attorney: You acknowledge that You have been advised by the Company to consult an
attorney regarding the terms of this General Release before signing it, and state that You have consulted with your attorney regarding this General Release, and that in executing this General Release You have not relied upon any representations or
statements by the Company or any of its respective agents, representatives, employees, or attorneys regarding the subject matter, basis, or effect of this General Release. 
 JUDSON COOPER REPRESENTS THAT HE HAS READ THIS GENERAL RELEASE, THAT BASED THEREON, HE UNDERSTANDS ALL OF ITS TERMS, AND THAT HE ENTERS INTO THIS GENERAL RELEASE VOLUNTARILY AND WITH FULL KNOWLEDGE OF ITS EFFECT.

  

							
	  
	 		 		 	  

	Date	 		 		 	Signature
			
		 		 	LEV PHARMACEUTICALS, INC.
				
	  
	 		 	By:	 	  

	Date	 		 		 	
			
		 		 	VIROPHARMA INCORPORATED
				
	  
	 		 	By:	 	  

	Date	 		 		 	

  

 - 8 -Amendment to the License Agreement, by and between the Company and Beta Foods

 Exhibit 10.9 
 Beta Foods, LLC 
 13250 Gregg Street 
 Suite A 
 Poway, California 92064 
 May 14, 2004 
 American Consolidated Management Group,
Inc. 
 714 Fairview Road 
 Greer, South Carolina 29651

 Re: Amendment to Technology Transfer Agreement 
 Gentlemen:

 When accepted by you, this shall constitute our complete amendment to our agreement concerning the transfer to you of certain technology,
and the rights to manufacture, market, and distribute products made with the subject technology. 
 ACMG has negotiated a settlement and
compromise agreement by and between itself and AR Funding [“ARF”] concerning conflicting claims as to debts claimed, and shares issued to Jack Shaw and Brian K. Holden. 
 Part of the consideration between ACMG and Beta in their original agreement was the issuance of shares of ACMG common stock, and the cleaning up of
indebtedness of ACMG in order to add value to ACMG. 
 In order to facilitate ACMG’s reduction of debt to ARF, Beta hereby agrees to the
following: 
  

	 	a.	Beta shall repay the principal sum of $ 2,640,000.00 to ARF; provided, that Beta’s liability is hereby expressly limited to, and contingent upon, the payment of the increased
royalty set out herein, such that the general assets of Beta shall not be subject to a charge by ARF for this indebtedness. This indebtedness is further limited to the increased portion of the royalty set out herein, and shall not be charged, or
chargeable against the current ten percent (10%) royalty between ACMG and Beta. Beta agrees to wire transfer to ARF the monthly royalty against which this indebtedness is chargeable, within 2 business days of receipt of said payments; provided
that, ARF has provided Beta with proper wiring instructions. 

  

	 	b.	 For and in consideration of this agreement, the monthly royalty payable to Beta by ACMG pursuant to the agreement, dated March 23, 2004, by and between ACMG
and Beta, shall be increased from ten percent (10%) to thirty percent (30%), with the increased portion [20%] to be utilized first for the 

  

 1 

	 	 
repayment to AFR of the debt listed hereinabove, and second for any increased income tax liability for Beta that results from the payment to Beta of the
increased royalty set out herein. In this regard, it is specifically agreed and understood that Beta is assuming, to the extent set out herein, the indebtedness set out hereinabove from ACMG, and that the purpose of that assumption is to facilitate
the start-up operations of ACMG in which Beta has a vested interest. Upon such time as the ARF debt is paid in full, as well as any additional compensation determined by competent tax advisors and/or counselors, to compensate and cover any increased
tax liabilities of Beta resulting from the payment of the ARF debt, then the increased royalty (20%) shall automatically revert back to ACMG. In this regard, Beta may elect to obtain independent tax counsel from either an attorney or certified
public accountant regarding the income tax liability consequences of this transaction. ACMG shall bear the costs of such opinion, and said opinion shall be binding upon ACMG, and shall control the length of time that this increased royalty shall be
in effect. 

 This amendment is specifically contingent upon the full and complete execution and delivery, in form and
substance satisfactory to ACMG, of a release of indebtedness by ARF of any and all claims by ARF against ACMG, as well as any subsidiary of ACMG, without conditions. In the event that said release is not executed and delivered to ACMG simultaneously
with this letter amendment, then in such event, this letter amendment shall automatically be void, regardless if executed and delivered. 
 Except as specifically amended herein, the terms and provisions of the original agreement, dated March 23, 2004 shall remain in full force and effect. 
 If the foregoing is your understanding of our agreement, and is completely satisfactory to you, please indicate your acceptance in the space provided below and return two copies to our offices. 
  

	
	Regards,
	
	Richard A, Shanks
	President

 Agreed to and accepted this 
 14th day of
May, 2004. 
  

			
	American Consolidated Management Group, Inc.
		
	By:	 	 

		 	Director

  

 2 

 Printed Name/Office 
  

			
	Agreed to and accepted by
Associated Receivables Funding, Inc.
on this 14th
day of May, 2004, for the express
limited purpose of agreeing to the repayment
of debt from and out of the royalty.
		
	By:	 	 

		 	Brian K. Holden

  

 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}]]